par Body, Jean-Jacques
Editeur scientifique Rosen, Clifford J
Référence Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, The American Society for Bone and Mineral Research & Wiley-Blackwell (John Wiley & Sons), Ed. 8, page (741-753)
Publication Publié, 2013
Partie d'ouvrage collectif
Résumé : According to various large series, up to 80-90% of patients with advanced cancer will develop bone metastases. The skeleton is the most common site of metastatic disease. It is also the most frequent site of first distant relapse in breast and prostate cancers. Metastatic bone disease causes considerable distress to breast cancer patients. Due to the long clinical course breast cancer may follow, morbidity due to tumor bone disease also makes major demands on resources for health care provision. Bone pain is a presenting feature in three-fourths of the patients with multiple myeloma. Bisphosphonates were first successfully used in tumor-induced hypercalcemia. Bisphosphonates, especially zoledronic acid, constitute an important part of our therapeutic armamentarium to reduce the skeletal morbidity rate in patients with bone metastases and to preserve bone health in patients with early stage breast cancer.